Your browser doesn't support javascript.
loading
FOXA2 activates HIF2α expression to promote tumor progression and is regulated by the E3 ubiquitin ligase VHL in renal cell carcinoma.
Yang, Dongjun; Li, Qixiang; Lu, Peifen; Wu, Dongliang; Li, Wenyang; Meng, Xingjun; Xing, Mengying; Shangguan, Wenbing; Chen, Bing; Yang, Jie; Zhang, Zhihong; Wang, Zengjun; Huang, David C S; Zhao, Quan.
Afiliação
  • Yang D; The State Key Laboratory of Pharmaceutical Biotechnology, Department of Hematology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, China-Australia Institute of Translational Medicine, School of Life Sciences, Nanjing University, Nanjing, China.
  • Li Q; The State Key Laboratory of Pharmaceutical Biotechnology, Department of Hematology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, China-Australia Institute of Translational Medicine, School of Life Sciences, Nanjing University, Nanjing, China.
  • Lu P; The State Key Laboratory of Pharmaceutical Biotechnology, Department of Hematology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, China-Australia Institute of Translational Medicine, School of Life Sciences, Nanjing University, Nanjing, China.
  • Wu D; The State Key Laboratory of Pharmaceutical Biotechnology, Department of Hematology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, China-Australia Institute of Translational Medicine, School of Life Sciences, Nanjing University, Nanjing, China.
  • Li W; The State Key Laboratory of Pharmaceutical Biotechnology, Department of Hematology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, China-Australia Institute of Translational Medicine, School of Life Sciences, Nanjing University, Nanjing, China.
  • Meng X; The State Key Laboratory of Pharmaceutical Biotechnology, Department of Hematology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, China-Australia Institute of Translational Medicine, School of Life Sciences, Nanjing University, Nanjing, China.
  • Xing M; The State Key Laboratory of Pharmaceutical Biotechnology, Department of Hematology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, China-Australia Institute of Translational Medicine, School of Life Sciences, Nanjing University, Nanjing, China.
  • Shangguan W; The State Key Laboratory of Pharmaceutical Biotechnology, Department of Hematology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, China-Australia Institute of Translational Medicine, School of Life Sciences, Nanjing University, Nanjing, China.
  • Chen B; The State Key Laboratory of Pharmaceutical Biotechnology, Department of Hematology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, China-Australia Institute of Translational Medicine, School of Life Sciences, Nanjing University, Nanjing, China.
  • Yang J; Department of Urology and Pathology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
  • Zhang Z; Department of Urology and Pathology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
  • Wang Z; Department of Urology and Pathology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
  • Huang DCS; Department of Medical Biology, The Walter and Eliza Hall Institute of Medical Research, University of Melbourne, Melbourne, Victoria, Australia.
  • Zhao Q; The State Key Laboratory of Pharmaceutical Biotechnology, Department of Hematology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, China-Australia Institute of Translational Medicine, School of Life Sciences, Nanjing University, Nanjing, China. Electronic address: qzhao@nju
J Biol Chem ; 300(1): 105535, 2024 Jan.
Article em En | MEDLINE | ID: mdl-38072043
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Fatores de Transcrição Hélice-Alça-Hélice Básicos / Fator 3-beta Nuclear de Hepatócito / Neoplasias Renais Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Fatores de Transcrição Hélice-Alça-Hélice Básicos / Fator 3-beta Nuclear de Hepatócito / Neoplasias Renais Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article